Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME9Q3V)

• Drug Name: Sch-45752 Drug Info
• Synonyms: Cephalochromin; MLS000876993; CHEMBL463175; NSC627953; NSC201419; 25908-26-3; SMR000440611; cefalochromin; 5,6,8-trihydroxy-2-methyl-9-(5,6,8-trihydroxy-2-methyl-4-oxo-2,3-dihydrobenzo[g]chromen-9-yl)-2,3-dihydrobenzo[g]chromen-4-one; Sch 45752; AC1Q6DTF; AC1L4N2K; SCHEMBL1111561; MEGxm0_000312; cid_160115; ACon0_000585; ACon1_000126; MolPort-001-739-590; HMS2270H11; BDBM50269745; NSC-201419; NSC-627953; MCULE-6609850631; NCGC00180856-01; SR-01000758207; SR-01000758207-2; CEPHALOCHROMIN

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 160115
  CAS Number: CAS 25908-26-3
  TTD Drug ID: DME9Q3V

Molecule-Related Drug Atlas

Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Obatoclax	DMPF9ZM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
AZD5991	DM7QGHO	Haematological malignancy	2B33.Y	Phase 1	[5]
AMG 176	DM0Q7NO	Acute myeloid leukaemia	2A60	Phase 1	[5]
PRT1419	DMIKE0O	Melanoma	2C30	Phase 1	[6]
ABBV-467	DM87SM9	Multiple myeloma	2A83	Phase 1	[7]
MIK665	DMTUVCG	Acute myeloid leukaemia	2A60	Phase 1	[8]
AMG 397	DM7CNTG	Refractory hematologic malignancy	2A85.5	Phase 1	[9]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[10]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[10]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[10]

Drug(s) Targeting Phosphodiesterase (PDE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NM-702	DMDJLY9	Angina pectoris	BA40	Phase 3	[11]
M-518101	DMZ6VD5	Plaque psoriasis	EA90.0	Phase 3	[12]
Piroximone	DMQXJDM	Cardiac failure	BD10-BD13	Discontinued in Phase 3	[13]
AA-2379	DM78623	Inflammation	1A00-CA43.1	Discontinued in Phase 2	[14]
HN-10200	DMYJ1ZB	Cardiac failure	BD10-BD13	Discontinued in Phase 2	[15]
TIBENELAST	DMYH2PU	Asthma	CA23	Discontinued in Phase 2	[16]
ALBIFYLLINE	DMVBKLO	Sepsis	1G40-1G41	Discontinued in Phase 1	[17]
Isomazole	DM4YJ2W	Asthma	CA23	Terminated	[18]
BBB-022	DMITV4F	Cerebrovascular ischaemia	8B1Z	Terminated	[19]
JTT-608	DMZBNHC	Diabetic complication	5A2Y	Terminated	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[2]
Phosphodiesterase (PDE)	TTUST1O	NOUNIPROTAC	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002639)
• [2] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [3] SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13.
• [4] Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of Prelude Therapeutics.
• [7] Clinical pipeline report, company report or official report of AbbVie.
• [8] MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
• [9] Clinical pipeline report, company report or official report of Amgen.
• [10] Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
• [11] The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14.
• [14] Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55.
• [15] HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65.
• [16] Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology. 1993;46(3):142-7.
• [17] Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53.
• [18] Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97.
• [19] Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400.
• [20] JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9.